- Home
- YETI vs ZLAB Comparison
YETI vs ZLAB Comparison
Compare YETI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YETI
- ZLAB
- Stock Information
- Founded
- YETI 2006
- ZLAB 2013
- Country
- YETI United States
- ZLAB China
- Employees
- YETI N/A
- ZLAB N/A
- Industry
- YETI Recreational Games/Products/Toys
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- YETI Consumer Discretionary
- ZLAB Health Care
- Exchange
- YETI Nasdaq
- ZLAB Nasdaq
- Market Cap
- YETI 3.0B
- ZLAB 3.0B
- IPO Year
- YETI 2018
- ZLAB 2017
- Fundamental
- Price
- YETI $39.60
- ZLAB $26.43
- Analyst Decision
- YETI Buy
- ZLAB Strong Buy
- Analyst Count
- YETI 12
- ZLAB 4
- Target Price
- YETI $45.33
- ZLAB $52.50
- AVG Volume (30 Days)
- YETI 2.2M
- ZLAB 1.3M
- Earning Date
- YETI 11-07-2024
- ZLAB 11-12-2024
- Dividend Yield
- YETI N/A
- ZLAB N/A
- EPS Growth
- YETI 217.19
- ZLAB N/A
- EPS
- YETI 2.31
- ZLAB N/A
- Revenue
- YETI $1,803,126,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- YETI $12.80
- ZLAB $48.50
- Revenue Next Year
- YETI $7.38
- ZLAB $47.37
- P/E Ratio
- YETI $17.12
- ZLAB N/A
- Revenue Growth
- YETI 13.62
- ZLAB 35.01
- 52 Week Low
- YETI $33.41
- ZLAB $13.48
- 52 Week High
- YETI $54.16
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- YETI 55.42
- ZLAB 44.26
- Support Level
- YETI $36.78
- ZLAB $24.85
- Resistance Level
- YETI $42.42
- ZLAB $26.77
- Average True Range (ATR)
- YETI 1.86
- ZLAB 1.57
- MACD
- YETI 0.12
- ZLAB -0.70
- Stochastic Oscillator
- YETI 68.70
- ZLAB 20.71
About YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.